Jean-Thomas Vilquin

PROMETHERA Biosciences SA discovers, develops and commercializes cell therapy products to treat liver diseases. It operates as a pharmaceutical company that develops treatment based on allogeneic adult stem cell technology. The firm’s technology platform is based on a newly discovered cell type, isolated from normal human adult liver tissue: Heterologous Human Adult Liver Progenitor Cells (HHALPC). The company was founded by Etienne Marc Sokal and Eric Halioua on February 12, 2009 and is headquartered in Mont-Saint-Guibert, Belgium.

Horama SA engages in the development of gene therapies, It focuses on ophthalmological diseases for preserving visual autonomy of patients. The company was founded by Denis Cayet, Christian Hamel, Guylene Le Meur, Philippe Moullier, Vasiliki Kalatzis, and Michel Weberin March 2014 and is headquartered in Paris, France.

Maisons & Cités d'HLM provides real estate services. It offers builds social housing, as well as offers renting, selling, and buying of properties. The company was founded on December 31, 1985 and is headquartered in Douai, France.

Dynacure SA is a clinical-stage company, which engages in developing and commercializing novel therapies to transform the lives of patients with rare diseases who have limited or no treatment options. Its product includes, DYN101, an antisense oligonucleotide, or ASO, designed to be a disease-modifying medicine for treatment of the majority of ntronuclear myopathies patients with multiple mutations in adult and pediatric populations. The company was founded by Belinda Cowling in 2016 and is headquartered in Illikirch-Graffenstaden, France.

Shire Pharmaceuticals, Inc. manufactures pharmaceutical products. The company offers solutions for attention deficit & hyperactivity disorder, human genetic therapies, gastrointestinal, and renal diseases. The company was founded in 1986 and is headquartered in Wayne, PA

Shire Human Genetic Therapies, Inc. develops medicines for the treatment of genetic diseases. The company was founded on July 7, 1988 and is headquartered in Lexington, MA.

Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA.

Pervasis Therapeutics, Inc. is a clinical stage company developing a broad portfolio of biologically active therapeutics. The company was founded by Robert S. Langer Jr. and Helen Marie Nugent in 2004 and is headquartered in Waltham, MA.

Epygon SASU develops mitral valve instruments. It also engages in the research and development in physical and natural sciences. The company was founded by Marcio Scorsin and Enrico Pasquino on December 28, 2011 and is headquartered in Paris, France.

Part of PDC Line Pharma SASU, PDC Line Pharma is a Belgian company that focuses on medical needs, particularly on skin cancer, which is the most lethal form of cancer worldwide. The company is based in Liege, Belgium, and has two drug candidates in its pipeline, one for melanoma and another for lung cancer. The company aims to address this issue by developing drug candidates that can bring positive results to patients. PDC Line Pharma was founded in 2016 by Laurent Levy and Joel Plumas, and its CEO is Eric Halioua.

PDC Line Pharma SASU develops an active immuno-therapies for cancer based on an allogeneic cell line of Plasmacytoid Dendritic cells (PDC line) loaded with cancer antigens. It offers PDC line which displays antigen presenting cell abilities allowing the priming of antitumor na?ve CD8+ cells in vitro and in vivo (humanized mouse model). The company was founded by Laurent Levy and Joel Plumas in April 2014 and is headquartered in Grenoble, France.

Bioxodes SA develops pharmaceutical products. Its programme Ir-CPI, is the first in a novel class of antithrombotics, and is developed for the prevention of thrombosis in a range of applications including cardiopulmonary bypass grafting and percutaneous coronary intervention. The company was founded by Edmond Godfroid and Michel Guyaux on April 20, 2010 and is headquartered in Marche-en-Famenne, Belgium.

Arthur D. Little, Inc. engages in the provision of management consulting services. It specializes in strategy and organization, operations management, technology and innovation management, corporate finance, and global carbon advisory serving corporations and organizations worldwide. The firm serves the automotive, healthcare, information, chemicals, consumer goods, retail, manufacturing, and transportation industries. The company was founded by Arthur Dehon Little and Roger Griffin in October 1886 and is headquartered in Boston, MA.

European Biopharmaceutical Enterprises develops biological products. The private company is based in Brussels, Belgium.